SAN FRANCISCO, Oct. 15 /PRNewswire-FirstCall/ -- Stem cell approaches
in neurology and psychiatry is the focus of a new report released today by
NeuroInsights, the neurotech market authority. The industry insider report
on innovative research and development in stem cell technology for the
brain and nervous system provides unique insights into the key players and
competitive dynamics in this rapidly evolving field.
Stem cell companies focused on the central nervous system (CNS) have
the potential to address some of the largest unmet healthcare markets
including: Alzheimer's disease, amyotrophic lateral sclerosis, depression,
hearing loss, Huntington's disease, lysosomal storage disorders, multiple
sclerosis, Parkinson's disease, retinal disorders, spinal cord injury,
stroke, traumatic brain injury, and other brain and nervous system
disorders.
The report analyzes the scientific approaches and challenges to
utilizing stem cells in the CNS, discusses trends and drivers including
funding and regulatory issues, reveals promising treatment indications and
pipelines, examines business models leveraging the promise of stem cells,
and sheds light on investment opportunities and risks. It provides in-depth
profiles of twenty seven companies that are shaping the field and
spearheading the use of stem cells in the brain and nervous system.
The twenty seven trend setting companies reviewed in the report
include: Aastrom Biosciences, Advanced Cell Technology, ArunA Biomedical,
Athersys (Nasdaq: ATHX), Beike Biotechnology Company, BrainCells, Inc.,
BrainStorm Cell Therapeutics, California Stem Cell Inc., Cell Cure
Neurosciences, CellMed AG, Geron Corporation (Nasdaq: GERN), International
Stem Cell Corporation, NeuralStem, NeuroGeneration, NeuroNascent, NeuroNova
AB, Neuronyx, NsGene A/S, Pfizer Regenerative Medicine, Q Therapeutics,
ReNeuron Group (LSE: RENE.L), RhinoCyte, Stem Cell Sciences (LSE: STEM.L),
Stem Cell Therapeutics (TSX: SSS.V), Stem Cell Technologies, StemCells,
Inc. (Nasdaq: STEM), and Theradigm, Inc.
The 175 page report, "Stem Cell Approaches in Neurology and Psychiatry:
27 Trendsetters for 2009" is available immediately for download from
NeuroInsights at
http://www.neuroinsights.com/marketreports/stemcellreport.html or can be
ordered by calling NeuroInsights at 415-229-3225.
About NeuroInsights
NeuroInsights is the world's leading neurotechnology research and
advisory firm. As the neurotechnology market authority, NeuroInsights helps
investors, industry and society understand and profit from the rapid growth
in drugs, devices, cell-based therapeutics and diagnostics for the brain
and nervous system. NeuroInsights provides market reports, investment
information, industry events and strategic advisory services to venture
funds, startups, corporations, governments and financial institutions.
NeuroInsights created and maintains the NASDAQ(R) NeuroInsights(R)
Neurotech Index (Nasdaq: NERV), a pure play modified market-capitalization
weighted index designed to track the performance of the leading
neurotechnology companies which are listed and actively traded on one of
the three major U.S. stock exchanges.
Contact:
Casey Lynch,
Managing Director
NeuroInsights
clynch@neuroinsights.com
415-229-3225
http://www.neuroinsights.com
http://www.neurotechinsights.com
SOURCE NeuroInsights
 back to top
Related links:
http://www.neuroinsights.com
http://www.neurotechinsights.com
CONTACT:
Casey Lynch, Managing Director of
NeuroInsights, +1-415-229-3225, clynch@neuroinsights.com
|
